Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The last earnings update was 45 days ago. More info.
Syndax Pharmaceuticals has significant price volatility in the past 3 months.
1T3 underperformed the Biotechs industry which returned -10.2% over the past year.
1T3 underperformed the Market in Germany which returned -6% over the past year.
Is Syndax Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?
It is not possible to calculate the future cash flow value for Syndax Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is €5.441.
The amount the stock market is willing to pay for Syndax Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Are Syndax Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
** Primary Listing of Syndax Pharmaceuticals.
Syndax Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
Syndax Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Does Syndax Pharmaceuticals's expected growth come at a high price?
Unable to calculate PEG ratio for Syndax Pharmaceuticals, we can't assess if its growth is good value.
What value do investors place on Syndax Pharmaceuticals's assets?
* Primary Listing of Syndax Pharmaceuticals.
Syndax Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
Syndax Pharmaceuticals has a total score of 1/6, see the detailed checks below.
How is Syndax Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 7 analysts?
Is Syndax Pharmaceuticals expected to grow at an attractive rate?
Syndax Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Syndax Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
Syndax Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Syndax Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
Syndax Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
All data from Syndax Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
Unable to establish if Syndax Pharmaceuticals will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Syndax Pharmaceuticals has a total score of 5/6, see the detailed checks below.
How has Syndax Pharmaceuticals performed over the past 5 years?
Below we compare Syndax Pharmaceuticals's growth in the last year to its industry (Biotechs).
Syndax Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
Unable to compare Syndax Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
Unable to compare Syndax Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Syndax Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
It is difficult to establish if Syndax Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
It is difficult to establish if Syndax Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
It is difficult to establish if Syndax Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Syndax Pharmaceuticals has a total score of 0/6, see the detailed checks below.
How is Syndax Pharmaceuticals's financial health and their level of debt?
The boxes below represent the relative size of what makes up Syndax Pharmaceuticals's finances.
Syndax Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
Syndax Pharmaceuticals's cash and other short term assets cover its long term commitments.
This treemap shows a more detailed breakdown of Syndax Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Syndax Pharmaceuticals has no debt, it does not need to be covered by short term assets.
All data from Syndax Pharmaceuticals Company Filings, last reported 3 months ago.
Syndax Pharmaceuticals has no debt.
Syndax Pharmaceuticals had no debt 5 years ago.
Syndax Pharmaceuticals has sufficient cash runway for 1.2 years based on current free cash flow.
Syndax Pharmaceuticals has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 46.3% each year.
Syndax Pharmaceuticals has a total score of 6/6, see the detailed checks below.
What is Syndax Pharmaceuticals's current dividend yield, its reliability and sustainability?
Current annual income from Syndax Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Syndax Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Unable to evaluate Syndax Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
Unable to evaluate Syndax Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Unable to perform a dividend volatility check as Syndax Pharmaceuticals has not reported any payouts.
Unable to verify if Syndax Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
What portion of Syndax Pharmaceuticals's earnings are paid to the shareholders as a dividend.
Unable to calculate sustainability of dividends as Syndax Pharmaceuticals has not reported any payouts.
No need to calculate the sustainability of Syndax Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
What is the CEO of Syndax Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?
Dr. Briggs W. Morrison, M.D. serves as the Executive Partner MPM Capital. He joined MPM in 2015. He is the Chairman of Scientific Advisory Board at Cerenis Therapeutics Holding SA since May 2018. Dr. Morrison has been the Chief Executive Officer of Syndax Pharmaceuticals, Inc. since June 22, 2015. Dr. Morrison has been Managing Director at MPM Capital since June 22, 2015. Dr. Morrison joined MPM Capital in 2015. He served as an Executive Vice President for Global Medicines Development and Chief Medical Officer at AstraZeneca PLC from January 2012 to June 2015. In his role as Head of Global Medicines Development, Dr. Morrison oversaw all clinical development functions and late stage clinical development projects at AstraZeneca. During his tenure, AstraZeneca rebuilt its Phase 3 pipeline with a focus on Oncology, Respiratory and Cardiovascular/Metabolic molecules. He served as a Senior Vice President/Head of Clinical Development of Pfizer Inc. since October 4, 2007 until January 2012. He held a number of positions at Pfizer Inc. from 2007 to 2012 that culminated in his appointment as Head, Medical Affairs, Safety and Regulatory Affairs for Pfizerâ s human health business. Dr. Morrison serves as a Director of Arvinas, Inc since June 2018. Dr. Morrison was responsible for the clinical development of all compounds in Pfizer's portfolio, he played a key role in implementing strategies to advance key compounds to approval. He oversaw Phase I – III development for all therapeutic areas as well as clinical operations. He later oversaw Development, Medical Affairs, Safety and Regulatory Affairs for all Pfizer human health businesses and served as Head of the Medicines Development Group for the Primary Care Business Unit, overseeing Development, Medical Affairs, Market Access and early commercial development. Previously, Dr. Morrison served as Senior Vice President of Research Planning and Integration of Merck & Co., Inc. and its head of Global Clinical Development Operations. He served in senior research and clinical data management positions as Executive Director and Vice President for all Clinical Data Management Operations, where he was responsible for all clinical data management across the entire research portfolio. He worked at Merck Research Laboratories from 1995 to 2007, ascending to the role of Vice President, Clinical Sciences, Oncology, responsible for clinical development of all novel anti-cancer drugs. He also worked as the Head of the Oncology Development group at Merck & Co., Inc., overseeing the development and approval of vorinostat (Zolinza) for the treatment of cutaneous T-cell lymphoma. From 2004 to 2006, he was on a special assignment to review and enhance the effectiveness of Merck's research operations and led the restructuring of the research division and its processes. He served as Chairman of the Board of Transcelerate BioPharma from 2014 to 2015. He serves as Board of Director of ACRES (Alliance for Clinical Research Excellence and Safety), ImunoMet Therapeutics, Inc. and Oncorus, Inc. He has been a Director of RIFT Biotherapeutics Inc. since March 2017 and NextCure, Inc. since April 2019. He has been a Member of Advisory Board of Tyme Technologies, Inc. since September 14, 2017. Dr. Morrison has been a Director of Syndax Pharmaceuticals, Inc. since July 2015 and ImmunoMet Therapeutics, Inc. since November 28, 2017. He is an instructor in medicine at the Harvard Medical School. He completed his internship and residency in Internal Medicine at the Massachusetts General Hospital, a fellowship in Medical Oncology at the Dana-Farber Cancer Institute and a post-doctoral research fellowship in Genetics at Harvard Medical School. Dr. Morrison received a B.S. in Biology from Georgetown University and holds an M.D. from the University of Connecticut School of Medicine.
Briggs's compensation has increased whilst company is loss making.
Briggs's remuneration is higher than average for companies of similar size in Germany.
The tenure for the Syndax Pharmaceuticals management team is about average.
The average tenure for the Syndax Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
More shares have been bought than sold by Syndax Pharmaceuticals insiders in the past 3 months, but not in substantial volumes.
Syndax Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company’s lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1. It also develops entinostat with Keytruda (pembrolizumab) in a Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and melanoma or microsatellite stable colorectal carcinoma; with Tecentriq (atezolizumab) in a Phase Ib/II clinical trials to treat patients with triple-negative breast cancer, and HR+ and HER2- metastatic breast cancer; and with Bavencio (avelumab) in a Phase Ib/II clinical trials for the treatment of ovarian cancer. In addition, the company develops SNDX-6352, a monoclonal antibody that blocks the colony stimulating factor 1 that is in Phase I dose escalation trial in patients with chronic graft versus host disease; and as a monotherapy and in combination with Imfinzi (durvalumab), which is in Phase I/Ib dose trials for the treatment of solid tumors. Syndax Pharmaceuticals, Inc. has clinical collaborations with MSD International GmbH; Genentech, Inc.; Merck KGaA and Pfizer; and AstraZeneca plc. It also has collaborative research and development agreement with National Cancer Institute; clinical trial agreement with Eastern Cooperative Oncology Group; and license agreement with Kyowa Hakko Kirin Co., Ltd. The company was founded in 2005 and is headquartered in Waltham, Massachusetts.